Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy
Sharma et al.
Nature Communications
January 2020
Authors and Affiliates
Sharma M1, Khong H1, Fa'ak F1, Bentebibel SE1, Janssen LME1, Chesson BC1, Creasy CA1, Forget MA1, Kahn LMS1, Pazdrak B1, Karki B1, Hailemichael Y1, Singh M1, Vianden C1, Vennam S2, Bharadwaj U3, Tweardy DJ3, Haymaker C1, Bernatchez C1, Huang S4,5, Rajapakshe K4, Coarfa C4, Hurwitz ME6, Sznol M7, Hwu P1, Hoch U2, Addepalli M2, Charych DH2, Zalevsky J2, Diab A1, Overwijk WW8,9,10,11;
1
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
2
Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA.
3
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
4
Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, USA.
5
Dan L. Duncan Cancer Center, Houston, TX, USA.
6
Yale Comprehensive Cancer Center, New Haven, CT, USA.
7
Yale University Cancer Center, Yale University, New Haven, CT, USA.
8
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com.
9
Nektar Therapeutics, 455 Mission Bay Blvd South, San Francisco, CA, USA. woverwijk@nektar.com.
10
The University of Texas MD Anderson Cancer Center UT Health Graduate School of Biomedical Sciences, Houston, TX, USA. woverwijk@nektar.com.
11
Department of Immunology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. woverwijk@nektar.com.